Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30474193 | 0.79 | — | — | |
| SCHEMBL25310588 | 0.75 | AOC3 (0.39) | — | |
| SCHEMBL25844881 | 0.75 | TP53 (0.30) | — | |
| SCHEMBL26668984 | 0.73 | SLC5A2 (0.33) | MEN1ALDH1A1LMNAMAPTALOX12 | |
| SCHEMBL6027214 | 0.72 | PRKACA (0.41) | ALDH1A1 | |
| SCHEMBL31321097 | 0.71 | NPC1 (0.33) | MEN1MAPTKMT2A | |
| SCHEMBL21552685 | 0.70 | AOC3 (0.37) | — | |
| SCHEMBL12878756 | 0.70 | NPC1 (0.33) | MEN1ALDH1A1KMT2A | |
| SCHEMBL4491664 | 0.68 | TXNRD1 (0.50) | MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL26301910 | 0.68 | PDXK (0.47) | MEN1ALDH1A1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250250269-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2025-08-07 | — | — | US | disclosed |
| US-20250109148-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHANGHAI SHOUTI BIOTECHNOLOGY CO., LTD. (CN) | 2025-04-03 | — | — | US | disclosed |
| EP-4508047-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2025-02-19 | — | — | EP | disclosed |
| CN-119343339-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2025-01-21 | — | — | CN | disclosed |
| CN-119255988-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2025-01-03 | — | — | CN | disclosed |
| EP-4469444-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023198140-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2023-10-19 | — | — | WO | disclosed |
| WO-2023138684-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO , INC. (US) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250109148-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | MEN1 450/4885ALDH1A1 1901/4885LMNA 2536/4885 |
| US-20250250269-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, IAPP | MEN1 1383/4885ALDH1A1 2171/4885LMNA 3104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.